EcoDrugPlus

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSNBRG00000017100
Gene Symbol: LOC102792592
3 Cross references
260 Possible Orthologues:

Proteasome Subunit Beta Type-4-Like

Ensembl ID : ENSNBRG00000022315
Gene Symbol: LOC102791011
3 Cross references
214 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSNBRG00000018286
Gene Symbol: LOC102797877
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSNBRG00000023354
Gene Symbol: LOC102780585
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSNBRG00000000626
Gene Symbol: LOC102788351
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSNBRG00000001547
Gene Symbol: LOC102799431
3 Cross references
216 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSNBRG00000024271
Gene Symbol: LOC102788138
3 Cross references
202 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSNBRG00000020243
Gene Symbol: LOC102783802
3 Cross references
173 Possible Orthologues:

Proteasome Subunit Beta Type-9-Like

Ensembl ID : ENSNBRG00000020771
Gene Symbol: LOC102784825
3 Cross references
183 Possible Orthologues:

Proteasome Subunit Beta Type-9-Like

Ensembl ID : ENSNBRG00000024275
Gene Symbol: LOC102788707
3 Cross references
177 Possible Orthologues:

Protein Arginine N-Methyltransferase 5-Like

Ensembl ID : ENSNBRG00000018087
Gene Symbol: LOC102797577
3 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSNBRG00000001077
Gene Symbol: LOC102782140
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).